1Department of Radiation Oncology, Erasmus MC Daniel den Hoed Oncology Centre, Rotterdam, The Netherlands 2Department of Surgical Oncology, Erasmus MC Daniel den Hoed Oncology Centre, Rotterdam, The Netherlands.
Dis Colon Rectum. 2014 May;57(5):578-84. doi: 10.1097/DCR.0000000000000050.
Inguinal lymph node metastasis is predictive of locoregional recurrence and poor overall survival in anal carcinoma. Metachronous lymph node metastasis occurs in 10% of all anal cancer patients, but multiple studies have shown that the benefit of elective irradiation of the groin depends on T-stage, and the toxicity of groin irradiation must not be underestimated.
To analyze the inguinal recurrence rates among patients with anal carcinoma (T1-4, N0-1) who did not receive elective irradiation therapy to the groin and to determine predictors of inguinal recurrence.
Data on 119 patients treated between 1987 and 2005 were retrospectively analyzed. Patients were treated with 3-dimensional radiotherapy. The median dose was 60 Gy. During radiotherapy, 108 patients also received chemotherapy (5-fluorouracil and mitomycin-C).
AJCC staging showed a distribution of 21 T1 (18%), 58 T2 (49%), 27 T3 (23%), 13 T4 (11%), 101 N0 (85%) and 18 N1 (15%) tumors. The median follow up was 65 months (range, 1-240 months). The 5-year inguinal recurrence rate was 0% for T1, 10% for T2, 21% for T3 and 19% for T4 tumors (p = 0.034). T2 tumors of the perianal skin and the anal canal had 5-year inguinal recurrence rates of 12% and 8%, respectively. The 5-year inguinal recurrence rate was 21% for tumors ≥4 cm vs. 2% for tumors <4 cm in size (p = 0.003).
Eleven patients did not receive chemotherapy.
Elective irradiation of the groin should be considered for local control in patients (N0-N1) with T2 tumors ≥4 cm in size and/or located in the perianal skin, and in all patients with T3 and T4 tumors.
腹股沟淋巴结转移是肛门癌局部复发和总体生存不良的预测因素。10%的所有肛门癌患者会发生淋巴结转移,但多项研究表明,选择性照射腹股沟的益处取决于 T 期,并且不能低估腹股沟照射的毒性。
分析未接受选择性腹股沟照射的肛门癌(T1-4,N0-1)患者的腹股沟复发率,并确定腹股沟复发的预测因素。
回顾性分析 1987 年至 2005 年间治疗的 119 例患者的数据。患者接受三维放疗。中位剂量为 60 Gy。在放疗期间,108 例患者还接受了化疗(5-氟尿嘧啶和丝裂霉素 C)。
AJCC 分期显示 21 例 T1(18%)、58 例 T2(49%)、27 例 T3(23%)、13 例 T4(11%)、101 例 N0(85%)和 18 例 N1(15%)肿瘤。中位随访时间为 65 个月(范围,1-240 个月)。T1 肿瘤的 5 年腹股沟复发率为 0%,T2 肿瘤为 10%,T3 肿瘤为 21%,T4 肿瘤为 19%(p = 0.034)。肛周皮肤和肛门管的 T2 肿瘤的 5 年腹股沟复发率分别为 12%和 8%。肿瘤≥4 cm 的患者 5 年腹股沟复发率为 21%,肿瘤<4 cm 的患者为 2%(p = 0.003)。
11 例患者未接受化疗。
对于肿瘤大小≥4 cm 且/或位于肛周皮肤的 T2 肿瘤以及所有 T3 和 T4 肿瘤的患者,应考虑选择性照射腹股沟以控制局部复发。